Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eleni Athan is active.

Publication


Featured researches published by Eleni Athan.


Circulation | 1996

Apoptosis of Cardiac Myocytes During Cardiac Allograft Rejection: Relation to Induction of Nitric Oxide Synthase

Matthias Szabolcs; Robert E. Michler; Xiaochun Yang; Walif Aji; Dilip K. Roy; Eleni Athan; Robert R. Sciacca; Oktavjian P. Minanov; Paul J. Cannon

BACKGROUND Apoptosis is a distinct form of programmed cell death characterized by activation of endonucleases that cleave nuclear DNA, condensation and fragmentation of nuclear chromatin, blebbing of intact membranes, and cell shrinkage and fragmentation. The mechanisms responsible are unclear, but nitric oxide (NO) generated by inducible NO synthase (iNOS) has been demonstrated to induce apoptosis in macrophages in vitro. This study investigated whether apoptosis occurs during cardiac allograft rejection and examined the relationship of apoptosis to iNOS expression. METHODS AND RESULTS Heterotopic abdominal transplantation from Lewis to Wistar-Furth rats was used as a model of cardiac allograft rejection; Lewis-to-Lewis grafts served as controls. Apoptosis was identified by DNA ladders after electrophoresis on agarose gels and by in situ labeling of DNA fragments; cell types were determined by immunohistochemistry. The number of apoptotic cardiac myocytes increased sharply from day 3 (0.31/mm2 ventricular tissue) to day 5 (1.27/mm2) after transplantation. At day 5, allografts showed a significant increase (P < .01) in apoptotic cardiac myocytes, macrophages, and endothelial cells compared with syngeneic grafts. The expression of iNOS mRNA, protein, and enzyme activity paralleled in time and extent the apoptosis of cardiac myocytes. iNOS immunostaining of infiltrating macrophages and cardiac muscle fibers increased significantly in the allografts at days 3 to 5 and was accompanied by immunostaining of both cell types for nitrotyrosine, which is indicative of peroxynitrite formation. CONCLUSIONS Apoptosis of myocardial cells occurs during cardiac allograft rejection. Apoptosis during rejection parallels the expression of iNOS, which suggests that apoptosis may be triggered by NO and peroxynitrite.


American Journal of Physiology-heart and Circulatory Physiology | 1999

Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture

David J. Pinsky; Walif Aji; Matthias Szabolcs; Eleni Athan; Youping Liu; Yi Ming Yang; Richard P. Kline; Kim E. Olson; Paul J. Cannon

Excessive nitric oxide (NO) production within the heart is implicated in the pathogenesis of myocyte death, but the mechanism whereby NO kills cardiac myocytes is not known. To determine whether NO may trigger programmed cell death (apoptosis) of adult rat ventricular myocytes in culture, the NO donor S-nitroso- N-acetylpenicillamine (SNAP) was shown to kill purified cardiac myocytes in a dose-dependent fashion. In situ analysis of ventricular myocytes plated on chamber slides using nick-end labeling of DNA demonstrated that SNAP induces cardiac myocyte apoptosis, which was confirmed by the identification of oligonucleosomal DNA fragmentation on agarose gel electrophoresis. Similarly, treatment of cardiac myocytes with cytokines that induce inducible NO synthase was shown to cause an NO-dependent induction of apoptosis. Addition of reduced hemoglobin to scavenge NO liberated by SNAP extinguished both the increase in percentage of apoptotic cells and the appearance of DNA ladders. Treatment with SNAP (but not with N-acetylpenicillamine or SNAP + hemoglobin) not only induced apoptosis but resulted in a marked increase in p53 expression in cardiac myocytes detected by Western blotting and immunohistochemistry. These data indicate that NO has the capacity to kill cardiac myocytes by triggering apoptosis and suggest the involvement of p53 in this process.Excessive nitric oxide (NO) production within the heart is implicated in the pathogenesis of myocyte death, but the mechanism whereby NO kills cardiac myocytes is not known. To determine whether NO may trigger programmed cell death (apoptosis) of adult rat ventricular myocytes in culture, the NO donor S-nitroso-N-acetylpenicillamine (SNAP) was shown to kill purified cardiac myocytes in a dose-dependent fashion. In situ analysis of ventricular myocytes plated on chamber slides using nick-end labeling of DNA demonstrated that SNAP induces cardiac myocyte apoptosis, which was confirmed by the identification of oligonucleosomal DNA fragmentation on agarose gel electrophoresis. Similarly, treatment of cardiac myocytes with cytokines that induce inducible NO synthase was shown to cause an NO-dependent induction of apoptosis. Addition of reduced hemoglobin to scavenge NO liberated by SNAP extinguished both the increase in percentage of apoptotic cells and the appearance of DNA ladders. Treatment with SNAP (but not with N-acetylpenicillamine or SNAP + hemoglobin) not only induced apoptosis but resulted in a marked increase in p53 expression in cardiac myocytes detected by Western blotting and immunohistochemistry. These data indicate that NO has the capacity to kill cardiac myocytes by triggering apoptosis and suggest the involvement of p53 in this process.


Circulation | 2000

Upregulation of COX-2 During Cardiac Allograft Rejection

Xiaochun Yang; Ninsheng Ma; Matthias Szabolcs; Jing Zhong; Eleni Athan; Robert R. Sciacca; Robert E. Michler; Gary D. Anderson; Joseph F. Wiese; Kathleen M. Leahy; Susan A. Gregory; Paul J. Cannon

BACKGROUND The hypothesis that cyclooxygenase-2 (COX-2) is involved in the myocardial inflammatory response during cardiac allograft rejection was investigated using a rat heterotopic abdominal cardiac transplantation model. METHODS AND RESULTS COX-2 mRNA and protein in the myocardium of rejecting cardiac allografts were significantly elevated 3 to 5 days after transplantation compared with syngeneic controls (n=3, P<0.05). COX-2 upregulation paralleled in time and extent the upregulation of iNOS mRNA, protein, and enzyme activity in this model. COX-2 immunostaining was prominent in macrophages infiltrating the rejecting allografts and in damaged cardiac myocytes. Prostaglandin (PG) levels in rejecting allografts were also higher than in native hearts. Because NO has been reported to modulate PG synthesis by COX-2, additional transplants were performed using animals treated with a selective COX-2 inhibitor (SC-58125) and a selective inhibitor of the inducible nitric oxide synthase (iNOS) N-aminomethyl-L-lysine. At posttransplant day 5, inhibitor administration resulted in a significant reduction of COX-2 mRNA expression (3764+/-337 versus 5110+/-141 arbitrary units, n=3, P<0.05) and iNOS enzymatic activity (1.7+/-0.4 versus 22.8+/-14. 4 nmol/mg protein, n=3, P<0.01) compared with vehicle-treated allogeneic transplants. Allograft survival in treated animals was increased modestly from 5.4 to 6.4 days (P<0.05). However, apoptosis of cardiac myocytes (TUNNEL method) was only marginally reduced relative to vehicle controls in treated graft recipients. The intensity of allograft rejection was also similar in the treated and untreated allografts. CONCLUSIONS The data indicates that COX-2 expression is enhanced in parallel with iNOS in the myocardium during cardiac allograft rejection.


Circulation | 2001

Acute Cardiac Allograft Rejection in Nitric Oxide Synthase-2−/− and Nitric Oxide Synthase-2+/+ Mice Effects of Cellular Chimeras on Myocardial Inflammation and Cardiomyocyte Damage and Apoptosis

Matthias Szabolcs; Ninsheng Ma; Eleni Athan; Jing Zhong; Ming Ming; Robert R. Sciacca; Jens Husemann; Arline Albala; Paul J. Cannon

Background—The contribution of nitric oxide synthase (NOS)-2 to myocardial inflammation and cardiomyocyte necrosis and apoptosis during allograft rejection was investigated through heterotopic cardiac transplantation in mice. Methods and Results—In the first experiments, hearts from C3H donor mice were transplanted into NOS-2−/− and NOS-2+/+ C57BL/6J.129J recipients. A second series of experiments included NOS-2−/− donor hearts transplanted into NOS-2−/− recipients and wild-type NOS-2+/+ donor hearts transplanted into wild-type NOS-2+/+ recipients. (All donors were C57BL/6J and recipients were C57BL/6J.129J.) In the first series of experiments, no significant differences were observed in allograft survival, rejection score, total number of apoptotic nuclei (TUNEL), total number of apoptotic cardiomyocytes, or graft NOS-2 mRNA and protein. Positive NOS-2 immunostaining occurred in endothelial cells and cardiomyocytes in the allografts; the inflammatory infiltrate was NOS-2 positive only when recipients were NOS-2+/+. In the second series of experiments, cardiac allograft survival was significantly increased in the NOS-2−/− mice (26±13 versus 17±8 days, P <0.05), along with significant reductions in inflammatory infiltrate, rejection score, and total number of apoptotic nuclei (23.5±9.5 versus 56.4±15.3, P <0.01) and of apoptotic cardiomyocytes (2.9±1.6 versus 6.9±2.7, P <0.05). No NOS-2 or nitrotyrosine, a marker of peroxynitrite exposure, was detected in NOS-2−/− allografts transplanted into NOS-2−/− recipients. ConclusionsThe data suggest that NO derived from NOS-2 contributes to the inflammatory response and to cardiomyocyte damage and apoptosis during acute cardiac allograft rejection.


BMC Medical Genetics | 2004

TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease

Quanyi Li; Eleni Athan; Michelle Wei; Eric Yuan; Samuel Rice; Jean Paul Vonsattel; Richard Mayeux; Benjamin Tycko

BackgroundThe p73 protein, a paralogue of the p53 tumor suppressor, is essential for normal development and survival of neurons. TP73 is therefore of interest as a candidate gene for Alzheimers disease (AD) susceptibility. TP73 mRNA is transcribed from three promoters, termed P1 – P3, and there is evidence for an additional complexity in its regulation, namely, a variable allelic expression bias in some human tissues.MethodsWe utilized RT-PCR/RFLP and direct cDNA sequencing to measure allele-specific expression of TP73 mRNA, SNP genotyping to assess genetic associations with AD, and promoter-reporter assays to assess allele-specific TP73 promoter activity.ResultsUsing a coding-neutral BanI polymorphism in TP73 exon 5 as an allelic marker, we found a pronounced allelic expression bias in one adult brain hippocampus, while 3 other brains (two adult; one fetal) showed approximately equal expression from both alleles. In a tri-ethnic elderly population of African-Americans, Caribbean Hispanics and Caucasians, a G/A single nucleotide polymorphism (SNP) at -386 in the TP73 P3 promoter was weakly but significantly associated with AD (crude O.R. for AD given any -386G allele 1.7; C.I. 1.2–2.5; after adjusting for age and education O.R. 1.5; C.I. 1.1–2.3, N= 1191). The frequency of the -386G allele varied by ethnicity and was highest in African-Americans and lowest in Caucasians. No significant differences in basal P3 promoter activity were detected comparing -386G vs. -386A promoter-luciferase constructs in human SK-NSH-N neuroblastoma cells.ConclusionsThere is a reproducible allelic expression bias in mRNA expression from the TP73 gene in some, though not all, adult human brains, and inter-individual variation in regulatory sequences of the TP73 locus may affect susceptibility to AD. However, additional studies will be necessary to exclude genetic admixture as an alternative explanation for the observed associations.


Cancer | 1992

T‐cell chronic lymphocytic leukemia. Unusual morphologic, phenotypic, and karyotypic features in association with light chain amyloidosis

Jay E. Gold M.D.; Ralph Zalusky; Anthony Louis-Charles; Violette S. Ghali; Arvind Babu; John R. Little; Eleni Athan; Daniel M. Knowles

Background. Lymphocytes that display a phenotype of mature B‐cells, T‐cells, natural killer (NK) cells, or a combination of T‐cells and NK cells can be found in patients with lymphoproliferations that manifest as expansions of peripheral blood lymphocytes (PBL). If these PBL expansions exhibit clonality, they can be classified as chronic lymphocytic leukemia (CLL).


JAMA | 2001

A Founder Mutation in Presenilin 1 Causing Early-Onset Alzheimer Disease in Unrelated Caribbean Hispanic Families

Eleni Athan; Jennifer Williamson; Alejandra Ciappa; Vincent Santana; Stavra N. Romas; Joseph H. Lee; Haydee Z. Rondon; Rafael Lantigua; Martin Medrano; Mayobanex Torres; Shigeki Arawaka; Ekaterina Rogaeva; You-Qiang Song; Christine Sato; Toshitaka Kawarai; Kimberley C. Fafel; Michael A. Boss; William Seltzer; Yaakov Stern; Peter St George-Hyslop; Benjamin Tycko; Richard Mayeux


American Journal of Pathology | 1991

bcl-1 rearrangement. Frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas.

Eleni Athan; D. R. Foitl; Daniel M. Knowles


JAMA Neurology | 2002

Polymorphisms in the Promoter of the Human APP Gene Functional Evaluation and Allele Frequencies in Alzheimer Disease

Eleni Athan; Joseph H. Lee; Alexander F. Arriaga; Richard Mayeux; Benjamin Tycko


American Journal of Pathology | 1992

The bcl-2 gene translocation is undetectable in Hodgkin's disease by southern blot hybridization and polymerase chain reaction

Eleni Athan; Amy Chadburn; Daniel M. Knowles

Collaboration


Dive into the Eleni Athan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge